<DOC>
	<DOCNO>NCT02849860</DOCNO>
	<brief_summary>Open-Label study design assess safety plasma PK tretinoin relevant metabolites topical dermal application IDP-121 lotion .</brief_summary>
	<brief_title>Absorption Systematic Pharmacokinetics IDP-121 Lotion Subjects With Acne Vulgaris</brief_title>
	<detailed_description>Open-Label study design assess safety plasma PK tretinoin relevant metabolites topical dermal application IDP-121 lotion subject moderate severe acne vulgaris maximal use condition .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Key Male female , age 9 &lt; 17 year ( 16 year 11 month inclusive ) . Written oral inform consent must obtain . Subjects less age consent must sign assent study parent legal guardian must sign informed consent . Subject must score 3 ( moderate ) 4 ( severe ) Evaluator 's Global Severity Assessment screen baseline visit facial area . Subjects facial acne inflammatory lesion count less 20 40 . Subjects facial acne noninflammatory lesion count less 20 100 . Key Use investigational drug device within 30 day enrollment participation research study concurrent study study . Any dermatological condition face could interfere clinical evaluation acne conglobate , acne fulminans , secondary acne , perioral dermatitis , clinical significant rosacea , gram negative folliculitis . Any underlying disease ( ) dermatological condition face require use interfere topical systemic therapy make evaluation lesion count inconclusive . Subjects facial beard mustache could interfere study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>